Phase 2 N=157 AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia
Hypercholesterolemia
Primary: Percent Change From Baseline in LDL-C at 8 Weeks — 2; -42; -16; -37 Percent Change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=97 Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women
Postmenopausal Osteoporosis
Primary: % Change From Baseline BMD in L1-L4 Axial Lumbar Spine at Week 24 — 5.07; 2.21; -0.17 percentage of change
Phase 2 N=159 Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.
Cachexia
Primary: The Efficacy of GTx-024 on Total Body Lean Mass. — 1.55; 0.98; 0.02 kg
Phase 2 N=16 Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease
Cystic Fibrosis
Primary: Change in Mucociliary Clearance — 7.4; 9.5 percent clearance
Phase 2 N=29 Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery
Esophageal Cancer
Primary: Pathologic Complete Response — 16.7 percentage of participants
Phase 2 N=36 HIV and Fat Accumulation
HIV Infection
Primary: Median Change in Visceral Adipose Tissue (VAT) Volume — -4.6 cm^2
Phase 2 N=47 Craving and Lifestyle Management Through Mindfulness Study
Obesity
Primary: Change in Abdominal Fat — 68.2; 50.0 grams
Phase 2 N=423 A Locally Injected Bradykinin Antagonist for TReatment of OSteoarthritiS
Osteoarthritis, Knee
Primary: WOMAC VA 3.1 A Score (Total Pain) — -60; -58; -52; -67 mm — p=0.5263
Phase 2 N=139 A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)
Dementia With Lewy Bodies (DLB)
Primary: Cognitive Function: Change From Baseline in Mini-mental State Examination (MMSE) Total at Week 12 Last Observation Carried Forward (LOCF) — 20.1; 19.7; 19.7; 18.2 Score…
Phase 2 N=37 Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: One-year Survival, The Percentage of Patients Who Are Alive One Year After Completing Protocol Treatment — 54 percentage of participants
Phase 2 N=53 The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial
Cognitive Impairment · Hypertension · Aging
Primary: Cognitive Assessment: Trail Making Test Part B — -14; 17; 4 seconds — p=0.008
Phase 2 N=99 Febuxostat Versus Allopurinol or Placebo in Patients With Hyperuricosuria and Calcium Oxalate Stones
Hyperuricosuria · Kidney Stones
Primary: Percent Change From Baseline to Month 6 in 24-hour Urine Uric Acid (uUA) Excretion — -58.6; -36.4; -12.7 percent change — p=<0.001
Phase 2 N=79 Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer
Breast Cancer · Breast Neoplasms
Primary: Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease…
Phase 2 N=27 Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)
HIV Infections
Primary: Anti-Tat Antibody Titer — 698; 4 ng/mL
Phase 2 N=146 Dose-Tolerability Titration Study to Evaluate The Efficacy And Safety Of Perampanel (E2007) In Patients With Post-Herpetic Neuralgia (PHN)
Neuralgia
Primary: Change From Baseline in Average Pain Scores to Week 15/ End of Treatment (EOT) (Including Modified BOCF Data) — -0.55; -1.30; -0.95; -0.50 Scores on a scale